![Todd Bazemore](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Todd Bazemore
Directeur/Bestuurslid bij
PULMATRIX, INC.
Vermogen: 647 $ op 31-05-2026
Profiel
Todd Bazemore is President, Chief Executive Officer & Director at Airna, Inc. since 2026.
Mr. Bazemore is Independent Director at Pulmatrix, Inc. since 2020.
Former positions include Director at Kala Bio, Inc. from 2025 to 2026; Vice President-Managed Markets at Sumitomo Pharma America, Inc. from 2012 to 2013; Chief Commercial Officer & Executive Vice President at Dyax Corp.
from 2014 to 2016; Chief Operating Officer & Executive Vice President at Santhera Pharmaceuticals Holding AG from 2016 to 2017; and Chief Operating Officer & Executive Vice President at Santhera Pharmaceuticals (USA), Inc. from 2016 to 2017.
Education includes undergraduate studies at the University of Massachusetts Lowell.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 29-12-2025 | 290 ( 0% ) | 647 $ | 31-05-2026 | |
PULMATRIX INC -.--% | 23-02-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
Actieve functies van Todd Bazemore
| Bedrijven | Functie | Begin |
|---|---|---|
| PULMATRIX, INC. | Directeur/Bestuurslid | 01-10-2020 |
Airna, Inc.
 Airna, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of RNA editing therapeutics | Algemeen Directeur | 02-06-2026 |
Eerdere bekende functies van Todd Bazemore
| Bedrijven | Functie | Einde |
|---|---|---|
| KALA BIO, INC. | Algemeen Directeur | 23-11-2025 |
| SANTHERA PHARMACEUTICALS HOLDING AG | Operationeel Directeur | 01-11-2017 |
Santhera Pharmaceuticals (USA), Inc.
 Santhera Pharmaceuticals (USA), Inc. Pharmaceuticals: MajorHealth Technology Develops and wholesales medicines for other diseases with high unmet medical needs | Operationeel Directeur | 01-11-2017 |
| DYAX CORP. | Corporate Officer/Principal | 22-01-2016 |
Sumitomo Pharma America, Inc.
 Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Corporate Officer/Principal | 01-09-2013 |
Opleiding van Todd Bazemore
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
30
Eerstegraads connecties
8
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Health Technology |
Dyax Corp.
 Dyax Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in development and commercialization of novel biotherapeutics | Health Technology |
Kala Bio, Inc.
 Kala Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company developing mesenchymal stem cell secretive (MSC-S) therapies | Health Technology |
Santhera Pharmaceuticals Holding AG
 Santhera Pharmaceuticals Holding AG Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for the treatment of neuromuscular diseases | Health Technology |
University of Massachusetts Lowell
 University of Massachusetts Lowell Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pulmatrix, Inc.
 Pulmatrix, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for pulmonary disease | Health Technology |
Santhera Pharmaceuticals (USA), Inc.
Santhera Pharmaceuticals (USA), Inc. Pharmaceuticals: MajorHealth Technology Develops and wholesales medicines for other diseases with high unmet medical needs | Health Technology |
Airna, Inc.
Airna, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovery and development of RNA editing therapeutics | Commercial Services |
